BDNF as a Biomarker for Spinocerebellar Ataxia

Spinocerebellar ataxia is a neurodegenerative disease, affecting 1 to 5 people per 100,000. The identification of biomarkers can provide key insights into the state and progression of a disease, in addition to patient response to treatments. As such, biomarkers can improve the success rates of drug development, accelerating the availability of new therapeutics.

0 min read
Written by
Anna Tzani
  • Categories
  • Biomarkers
Receive the latest newsletter directly to your inbox

The Spinocerebellar Ataxia Landscape

Identifying Biomarkers of SCA1

Examining the Biomarker Potential of BDNF



More on Biomarkers